East Bay biotech scores $42 million with potential quick-fix for heart trouble

Promising to make treating an irregular heartbeat as easy as a few breaths, an East Bay company has raised $42 million as it pushes an inhaled form of a longtime generic drug into a mid-stage clinical trial.

InCarda Therapeutics Inc. — a Newark company with connections to Gilead Sciences Inc. — believes its drug-device will work faster and more conveniently to deliver the generic drug flecainide to the hearts of people experiencing paroxysmal atrial fibrillation, a type of irregular heartbeat.